Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Hemostatic Disorders”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMed1996

Role of fibrin sealants in surgical procedures on patients with hemostatic disorders.

Fibrin sealants have until now been used to a very limited extent in patients with a bleeding diathesis. The authors have accumulated experience from 8 minor and 40 major surgical procedures, plus 10 circumcisions and 118 tooth extractions in 106 patients suffering from hemophilia A, B, or von Willebrand's disease. Most of the patients had the severe form of the disease. The authors were able to show a reduction of blood loss and of requirements for replacement therapy with factor concentrates. The literature on the application of fibrin sealants in this group of patients, which mainly deals with dental procedures, is reviewed and compared with data from the current study. The composition of the glue is of major significance and is discussed in detail.

Blood Coagulation Disorders↗
PubMed1976

[Hemostatic disorders with secretolytics? A contribution to drug safety].

Based on literature and on the results of this open clinical trial we conclude, that there is no connection between application of the above named group of drugs and the change in parameters of haemostasis function, which might lead to a manifest haemorrhagic diathesis. Within the period surveyed of 14 days no case of induced coagulopathy and particularly no thrombocytopenia was seen. The substances under consideration themselves did not exert any anticoagulatory effect nor did they potentiate or inhibit the effect of a concurrently given cumarin derivative.

Ambroxol↗
PubMed1999

[The evaluation of hemostatic disorders in patients with systemic lupus erythematosus].

AIM: Assessment of hemostasis in SLE patients. MATERIALS AND METHODS: We studied different coagulation parameters such as activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), activated clotting time (ACT); platelet aggregation (spontaneous and induced), fibrinolytic activity, concentration of fibrinogen, fibrinogen degradation products (FDP) and serotonin. RESULTS: Coagulation abnormalities were found with prevalence of hypercoagulation in APTT and TT tests. Fibrinolysis was inhibited. Levels of serotonin, FDP and spontaneous aggregation activity significantly increased. CONCLUSION: The above changes were typical for lingering DIC syndrome.

Adult↗
PubMedDate not supplied

[Role of oxidative stress as a component of critical states in the genesis of hemostatic disorders].

The effect of oxidative stress (OS) on hemostasis parameters was studied in model systems Fe(2+)-ascorbic acid-EDTA and Fe(2+)-EDTA-H2O2. Blood recalcification time, thrombin time, activated partial thromboplastin time, prothrombin index, the content of fibrinogen, antithrombin III, soluble fibrin-monomer complexes, platelet count and aggregation activity were evaluated. Parameters characterizing the severity of OS were measured: protein concentrations of carbonyl and sulfhydryl groups and level of malonic dialdehyde. OS was found to induce changes in the hemostasis system, promoting the progress of intravascular coagulation during the formation of critical state. The authors conclude that antioxidants should be added to combined therapy of blood clotting disorders in critical patients.

Adult↗
PubMed1992

[Hemostatic disorders in patients with HIV infection].

Impaired hemostasis was studied in 50 adult patients with HIV infection. The blood coagulative potential, the number and functional activity of platelets were examined. Platelet aggregation and secretion were shown to change earlier than thrombocytopenia developed and clinical signs of HIV infection appeared. The disturbance in the plasma section of hemostasis are due to concurrent opportunistic diseases and infections.

Acquired Immunodeficiency Syndrome↗
PubMed2006

The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders.

Rituximab is a chimeric anti-CD20 monoclonal antibody active against normal and malignant B cells which has proven to be effective in the therapy of CD-20 positive lymphomas. Its B-cell cytotoxic action has also been exploited in many non-malignant autoimmune disorders in which it has been used with the aim of interfering with the production of pathologic antibodies. The present knowledge regarding the use of rituximab in antibody-associated disorders of hemostasis (i.e. idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, acquired hemophilia A, congenital hemophilia with inhibitors, acquired inhibitors against coagulation factors) is presented briefly in this review. The results suggest that rituximab can be useful in the treatment of disorders of hemostasis associated with inhibitor formation. Although collectively the number of patients treated is now quite substantial, most of the data are drawn from isolated case reports or descriptions of small, uncontrolled series. Large, prospective, randomized trials are, therefore, needed to confirm the positive, preliminary results.

Adolescent↗
PubMed1991

[The Willebrand factor in the diagnosis of hemostatic disorders in patients with rheumatoid arthritis].

Studies of coagulation hemostasis in 108 patients with rheumatoid arthritis have revealed that high blood coagulation is characteristic of this disease, and a number of coagulation parameters (antithrombin III, fibrinogen, fibrinolytic activity, ethanol test) point to intravascular microthrombi formation (disseminated intravascular coagulation). Along with hemostasis investigations, Willebrand's factor levels were measured in the blood plasma of 44 patients. Enhancement of the inflammatory process activity was found to be associated with elevation of this factor level and augmentation of the blood coagulation activity. These results permit considering Willebrand's factor as one of the diagnostic criteria of thrombophilic conditions in patients with rheumatoid arthritis.

Adult↗
PubMed1990

[Pathogenetic characteristics of hemostatic disorders in chronic renal failure].

As many as 45 patients with terminal chronic renal failure (CRF) admitted to the hospital were examined for hemocoagulation and blood plasma content of medium-sized molecules (MSM). Animal (rabbit) experiments were made in vitro and in vivo to study the effect produced on hemocoagulation of MSM isolated from CFR patients' blood by acidic deproteinization, ultrafiltration and gel chromatography. Integrally, the MSM fraction was shown to exert marked anticoagulant and antiaggregation effects, to increase vascular permeability, promoting the development of hemorrhagic diathesis in CRF patients. Hemodialysis (HD) is an effective method for treating hemorrhagic diathesis of the given genesis. At the same time under the conditions of the presence of the cellular template (red blood cell hemolysis, platelet destruction as a result of HD) MSM may give rise to the development of thrombotic complications after HD completion and heparin neutralization. Therefore accumulation of MSM may play an important part in the onset of hemocoagulation disorders in patients with CRF.

Animals↗
PubMed1990

[Hemostatic disorders in anesthesiology and surgical intensive care].

Apart from straightforward haemorrhage, bleeding problems in anaesthesiology and intensive care are predominantly due to multifactorial haemostatic derangements caused by a depletion of procoagulant factors, inhibitors, and platelets. In certain settings, these events are complicated by an enhanced procoagulant and decreased fibrinolytic activity of the endothelium. This functional turnabout of the vasculature promotes disseminated intravascular coagulation (DIC). A rational therapeutic approach is based on estimates of the patient's losses and his volume of blood, adequate and repeated haemostatic monitoring, and an individually tailored substitution considering the critical levels of the informative parameters, i.e. the platelets, fibrinogen, Quick and aPTT, together with the haemostatic efficacy of the available preparations. Whenever possible, subclinical trends towards abnormal bleeding should be identified and countered by appropriate measures before an actual and potentially life-threatening haemostatic breakdown develops.

Anesthesia↗
PubMed1990

[The skin manifestations of congenital and acquired hemostatic disorders].

The authors review the literature data on skin symptoms of the most prevalent disorders induced by congenital or acquired defects of blood coagulation. The range of skin changes in hemostasis disorders includes hemorrhages of 5 various types, thromboses, pigmentation disorders, and pustular involvement. Early detection of skin symptoms of hemostasis disorders will improve the diagnosis and timely correction of such conditions.

Blood Coagulation Disorders↗
PubMed1990

[Hemostatic disorders in patients with Schoenlein-Henoch syndrome].

Several indices of coagulation and fibrinolysis were studied in 54 patients suffering from Schönlein-Henoch disease. A significant prolongation of platelet aggregation was found in parallel with a decrease of AT III and plasminogen and an increase of the fibrin monomer complexes. Consequent to heparin treatment controlled by measurements of residual thrombin activity, the indices showed a trend towards normalization. The dynamic monitoring of the above indices can be used for an overall assessment of the heparin treatment.

Adult↗